John A Kanis

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi request reprint A meta-analysis of prior corticosteroid use and fracture risk
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 19:893-9. 2004
  2. ncbi request reprint Optimization of BMD measurements to identify high risk groups for treatment--a test analysis
    Helena Johansson
    Statistician, Romelanda, Sweden
    J Bone Miner Res 19:906-13. 2004
  3. pmc Osteoporosis in the European Union: a compendium of country-specific reports
    A Svedbom
    OptumInsight, Stockholm, Sweden
    Arch Osteoporos 8:137. 2013
  4. doi request reprint Worldwide uptake of FRAX
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Arch Osteoporos 9:166. 2014
  5. ncbi request reprint Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 24:2763-4. 2013
  6. pmc SCOPE: a scorecard for osteoporosis in Europe
    J A Kanis
    University of Sheffield Medical School, Sheffield, UK
    Arch Osteoporos 8:144. 2013
  7. pmc European guidance for the diagnosis and management of osteoporosis in postmenopausal women
    J A Kanis
    WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 24:23-57. 2013
  8. doi request reprint The distribution of FRAX(®)-based probabilities in women from Japan
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    J Bone Miner Metab 30:700-5. 2012
  9. pmc A systematic review of hip fracture incidence and probability of fracture worldwide
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    Osteoporos Int 23:2239-56. 2012
  10. ncbi request reprint Assessment of fracture risk
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:581-9. 2005

Detail Information

Publications70

  1. ncbi request reprint A meta-analysis of prior corticosteroid use and fracture risk
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 19:893-9. 2004
    ..Current and past use of corticosteroids was an important predictor of fracture risk that was independent of prior fracture and BMD...
  2. ncbi request reprint Optimization of BMD measurements to identify high risk groups for treatment--a test analysis
    Helena Johansson
    Statistician, Romelanda, Sweden
    J Bone Miner Res 19:906-13. 2004
    ..Baseline assessment included hip BMD and clinical risk factors. Outcomes included death and fracture in women followed for 6723 person-years...
  3. pmc Osteoporosis in the European Union: a compendium of country-specific reports
    A Svedbom
    OptumInsight, Stockholm, Sweden
    Arch Osteoporos 8:137. 2013
    ..This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27)...
  4. doi request reprint Worldwide uptake of FRAX
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Arch Osteoporos 9:166. 2014
    ..The worldwide uptake of FRAX is described...
  5. ncbi request reprint Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 24:2763-4. 2013
    ....
  6. pmc SCOPE: a scorecard for osteoporosis in Europe
    J A Kanis
    University of Sheffield Medical School, Sheffield, UK
    Arch Osteoporos 8:144. 2013
    ..The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe...
  7. pmc European guidance for the diagnosis and management of osteoporosis in postmenopausal women
    J A Kanis
    WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 24:23-57. 2013
    ..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis...
  8. doi request reprint The distribution of FRAX(®)-based probabilities in women from Japan
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    J Bone Miner Metab 30:700-5. 2012
    ..The incorporation of FRAX into assessment guidelines is likely to redirect treatments for osteoporosis from younger women at low risk to elderly women at high fracture risk...
  9. pmc A systematic review of hip fracture incidence and probability of fracture worldwide
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    Osteoporos Int 23:2239-56. 2012
    ..There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries...
  10. ncbi request reprint Assessment of fracture risk
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:581-9. 2005
    ..Treatment can then be offered to those identified to have a fracture probability greater than an intervention threshold...
  11. ncbi request reprint The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield S10 2DU, UK
    Osteoporos Int 16:456-9, discussion 579-80. 2005
  12. ncbi request reprint Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 16:475-82. 2005
    ....
  13. pmc A reappraisal of generic bisphosphonates in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 23:213-21. 2012
    ..The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed...
  14. doi request reprint Assessment of fracture risk
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Eur J Radiol 71:392-7. 2009
    ..Fracture probability rather than BMD alone can be used to fashion strategies for the assessment and treatment of osteoporosis...
  15. ncbi request reprint Interpretation and use of FRAX in clinical practice
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:2395-411. 2011
    ..Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review..
  16. ncbi request reprint Pitfalls in the external validation of FRAX
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 23:423-31. 2012
    ..Recent studies have evaluated the performance of FRAX® in independent cohorts. The interpretation of most is problematic for reasons summarised in this perspective...
  17. ncbi request reprint A family history of fracture and fracture risk: a meta-analysis
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 35:1029-37. 2004
    ..Its identification on an international basis supports the use of this risk factor in case-finding strategies...
  18. ncbi request reprint Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 27:585-90. 2000
    ..The decrease in relative risk with age is, however, associated with an increase in absolute risk. Thus, for clinical use, the expression of absolute risks may be preferred to relative risks...
  19. ncbi request reprint Excess mortality after hospitalisation for vertebral fracture
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
    Osteoporos Int 15:108-12. 2004
    ..We conclude that a minority of deaths following hospitalization for vertebral fracture are attributable to the fracture itself under the assumptions we used...
  20. ncbi request reprint Epidemiology of osteoporosis and fracture in men
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Rd, Sheffield, United Kingdom S10 2RX
    Calcif Tissue Int 75:90-9. 2004
  21. ncbi request reprint Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial
    John A Kanis
    WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Bone 33:293-300. 2003
    ....
  22. ncbi request reprint The components of excess mortality after hip fracture
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Bone 32:468-73. 2003
    ..Hip fracture was a more common cause for mortality than pancreatic or stomach cancer. Thus, interventions that decreased hip fracture rate by, say, 50% would avoid 0.75% or more of all deaths...
  23. ncbi request reprint Diagnosis of osteoporosis and assessment of fracture risk
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield S10 2RX, UK
    Lancet 359:1929-36. 2002
    ..Many treatments can be provided cost-effectively to men and women if hip fracture probability over 10 years ranges from 2% to 10% dependent on age...
  24. ncbi request reprint Acute and long-term increase in fracture risk after hospitalization for stroke
    J Kanis
    Center for Metabolic Bone Diseases World Health Organization Collaborating Center, University of Sheffield Medical School UK
    Stroke 32:702-6. 2001
    ..The aims of this study were to determine the magnitude of the increase in fracture risk after hospitalization for stroke, and in particular to determine the time course of this risk...
  25. doi request reprint Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 27:1480-6. 2012
    ..Denosumab significantly decreased the risk of clinical osteoporotic fractures in postmenopausal women. Overall, the efficacy of denosumab was greater in those at moderate to high risk of fracture as assessed by FRAX...
  26. ncbi request reprint Alcohol intake as a risk factor for fracture
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:737-42. 2005
    ..We conclude that reported intake of alcohol confers a risk of some importance beyond that explained by BMD. The validation of this risk factor on an international basis permits its use in case-finding strategies...
  27. doi request reprint FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference
    Eugene V McCloskey
    University of Sheffield, Sheffield, UK
    J Clin Densitom 14:181-3. 2011
    ..This synthesis was presented to the expert panel and constitutes the data on which the subsequent Official Positions are predicated. A summary of the Clinical Task Force composition and charge is presented here...
  28. ncbi request reprint Cost-effectiveness of hormone therapy in the United States
    Ingrid Lekander
    i3 Innovus, Stockholm, Sweden
    J Womens Health (Larchmt) 18:1669-77. 2009
    ..To estimate the cost-effectiveness of 5 years of treatment with hormone therapy (HT) compared with no treatment for women with menopausal symptoms in the United States...
  29. doi request reprint Assessing the impact of osteoporosis on the burden of hip fractures
    Anders Oden
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Calcif Tissue Int 92:42-9. 2013
    ..We conclude that osteoporosis accounts for approximately half of all hip fractures. Strategies to prevent osteoporosis could save up to 50 % of all hip fractures...
  30. ncbi request reprint Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:6-14. 2005
    ....
  31. ncbi request reprint A meta-analysis of milk intake and fracture risk: low utility for case finding
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:799-804. 2005
    ..We conclude that a self-reported low intake of milk is not associated with any marked increase in fracture risk and that the use of this risk indicator is of little or no value in case-finding strategies...
  32. doi request reprint Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis
    Eugene V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 23:1561-8. 2008
    ..Having multiple vertebral fractures was associated with greater risk of incident osteoporotic fractures and hip fractures...
  33. doi request reprint Fracture risk assessment
    Eugene McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Clin Biochem 45:887-93. 2012
    ..Notwithstanding, the present models provide an aid to enhance patient assessment by the integration of clinical risk factors alone and/or in combination with BMD...
  34. doi request reprint A reference standard for the description of osteoporosis
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Bone 42:467-75. 2008
    ..5 SD or more below the average for young adult women. The adoption of DXA as a reference standard provides a platform on which the performance characteristics of less well established and new methodologies can be compared...
  35. ncbi request reprint Intervention thresholds for osteoporosis in the UK
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 36:22-32. 2005
    ....
  36. ncbi request reprint The perspective of the international osteoporosis foundation on the official positions of the international society for clinical densitometry
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, S10 2DU, Sheffield, UK
    J Clin Densitom 8:145-7. 2005
  37. ncbi request reprint Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study
    Fredrik Borgstrom
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    Pharmacoeconomics 22:1153-65. 2004
    ..The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis...
  38. ncbi request reprint A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, UK
    Bone 47:729-35. 2010
    ..There was no significant effect on non-vertebral fracture...
  39. ncbi request reprint From relative risk to absolute fracture risk calculation: the FRAX algorithm
    Eugene V McCloskey
    World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sorby Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, United Kingdom
    Curr Osteoporos Rep 7:77-83. 2009
    ..Notwithstanding, the present models provide an aid to enhance patient assessment by the integration of clinical risk factors alone and/or in combination with BMD. This article describes the steps undertaken in the development of FRAX...
  40. ncbi request reprint International variations in hip fracture probabilities: implications for risk assessment
    John A Kanis
    WHO Collaborating Center for Metabolic Bone Diseases, University of Sheffield Medical School, United Kingdom
    J Bone Miner Res 17:1237-44. 2002
    ..The categorization of hip fracture probabilities can be used to adjust intervention thresholds based on age, sex, and relative risk from a reference population such as Sweden...
  41. doi request reprint FRAX updates 2012
    Eugene McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK
    Curr Opin Rheumatol 24:554-60. 2012
    ..This brief review addresses the development of FRAX since then and describes some of the issues that continue to be discussed as FRAX plays an increasing role in clinical practice...
  42. doi request reprint Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Bone 44:1049-54. 2009
    ..No significant effect was noted on the risk of clinical fractures, but fracture risk reduction was reported in a post hoc subgroup analysis in a high risk group categorised on the basis of BMD and prior fracture...
  43. ncbi request reprint Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK
    Ingrid Lekander
    i3 Innovus, Klarabergsviadukten 90 Hus D, Stockholm, Sweden
    Menopause Int 15:19-25. 2009
    ..To estimate the cost-effectiveness of five-year treatment of hormone replacement therapy (HRT) compared with no treatment for women with menopausal symptoms in the UK...
  44. doi request reprint FRAX and its applications to clinical practice
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Bone 44:734-43. 2009
    ....
  45. ncbi request reprint A meta-analysis of reference markers of bone turnover for prediction of fracture
    Helena Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Calcif Tissue Int 94:560-7. 2014
    ..For the outcome of hip fracture, the association between s-CTX and risk of fracture was slightly higher, 1.23 (95 % CI 1.04-1.47). Thus, there is a modest but significant association between BTMs and risk of future fractures...
  46. doi request reprint Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®
    Eugene V McCloskey
    Academic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, UK
    J Clin Densitom 14:220-2. 2011
    ..More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®)...
  47. doi request reprint FRAX(®) with and without bone mineral density
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Calcif Tissue Int 90:1-13. 2012
    ....
  48. ncbi request reprint Approaches to the targeting of treatment for osteoporosis
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Nat Rev Rheumatol 5:425-31. 2009
    ..The tool increases sensitivity without trading specificity, and is now being used in the reappraisal of clinical guidelines...
  49. doi request reprint A meta-analysis of the association of fracture risk and body mass index in women
    Helena Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK Centre for Bone and Arthritis Research CBAR at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
    J Bone Miner Res 29:223-33. 2014
    ..At a population level, high BMI remains a protective factor for most sites of fragility fracture. The contribution of increasing population rates of obesity to apparent decreases in fracture rates should be explored...
  50. ncbi request reprint Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study
    Eugene McCloskey
    Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 19:728-36. 2004
    ..The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking...
  51. ncbi request reprint Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study
    Eugene V McCloskey
    Northern General Hospital, Sheffield, UK
    J Bone Miner Res 22:135-41. 2007
    ..The effect occurred in the absence of systematic calcium and vitamin D supplementation and was observed across a wide range of BMDs...
  52. ncbi request reprint Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study
    Patricia Clark
    Clinical Epidemiology Unit, CMN Siglo XXI IMSS Faculty of Medicine, UNAM, Mexico City, Mexico
    Osteoporos Int 16:2025-30. 2005
    ..5% in Mexican women and 3.8% in Mexican men. We conclude that hip fractures are an important health problem in Mexico and that Mexican health authorities should consider public health programs to prevent hip fractures...
  53. ncbi request reprint Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study
    Olof Johnell
    Department of Orthopaedics, Malmo General Hospital, Malmo, Sweden
    J Bone Miner Res 19:764-72. 2004
    ..The efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures...
  54. ncbi request reprint Potential impact of osteoporosis treatment on hip fracture trends
    L Joseph Melton
    J Bone Miner Res 20:895-7. 2005
  55. ncbi request reprint Predictive value of BMD for hip and other fractures
    Olof Johnell
    Department of Orthopaedics, Malmo University Hospital, Malmo, Sweden
    J Bone Miner Res 20:1185-94. 2005
    ..Low hip BMD was an important predictor of fracture risk. The prediction of hip fracture with hip BMD also depended on age and z score...
  56. ncbi request reprint Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men
    Patrick Haentjens
    Department of Orthopaedics and Traumatology, Vrije Universiteit Brussel, Brussels, Belgium
    J Bone Miner Res 19:1933-44. 2004
    ..These findings support the concept that forearm fracture is an early and sensitive marker of male skeletal fragility...
  57. ncbi request reprint Association between vertebral fracture and increased mortality in osteoporotic patients
    Tarja Jalava
    Leiras, Helsinki, Finland
    J Bone Miner Res 18:1254-60. 2003
    ..Prevalent vertebral fractures were associated with increased mortality, but other known predictors of mortality explain a significant proportion of the excess risk...
  58. ncbi request reprint The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks
    Tjeerd Peter van Staa
    Utrecht University, Utrecht, The Netherlands
    Value Health 10:348-57. 2007
    ..A pharmaco-economic model that used individualized risks for fractures was developed in order to take into account patient heterogeneity...
  59. ncbi request reprint The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach
    Chris De Laet
    Department of Public Health, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Osteoporos Int 16:313-8. 2005
    ..Case-finding strategies that combine clinical risk indicators with BMD have increased efficiency, while having a modest impact on the number of individuals requiring treatment. Therefore, the cost-effectiveness is enhanced...
  60. ncbi request reprint Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women
    Didier Hans
    Nuclear Medicine Division, Geneva University Hospital, Geneva, Switzerland
    J Bone Miner Res 23:1045-51. 2008
    ..9% to 26.6% and from 52.6% to 70.5% for SI Z-scores of +2 and -3, respectively. The combined use of CRFs and QUS SI is a promising tool to assess hip fracture probability in elderly women, especially when access to DXA is limited...
  61. ncbi request reprint Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS)
    Mark Lunt
    ARC Epidemiology Unit, University of Manchester, Manchester, UK
    Bone 33:505-13. 2003
    ..0 (95% CI;2.6, 6.0)). In summary, the risk of a subsequent vertebral fracture in individuals with preexisting deformities is importantly influenced by the characteristics of these deformities...
  62. ncbi request reprint Risk factors for incident vertebral fractures in men and women: the Rotterdam Study
    Marjolein van der Klift
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Bone Miner Res 19:1172-80. 2004
    ..In 3001 men and women from the Rotterdam Study, prevalent nonvertebral fractures, early menopause, current smoking, and walking aid use were also strong risk factors for incident vertebral fractures...
  63. ncbi request reprint Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
    Trevor Powles
    Royal Marsden National Health Service Trust, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 20:3219-24. 2002
    ..Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases...
  64. ncbi request reprint Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial
    Ingrid Lekander
    i3 Innovus, Vasagatan 38, SE 111 20 Stockholm, Sweden
    Bone 42:294-306. 2008
    ..The purpose of the study was to assess the cost effectiveness of hormone therapy (HT) for postmenopausal women without menopausal symptoms at an increased risk of fracture in Sweden, the UK and the US...
  65. ncbi request reprint Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study
    Yu Z Bagger
    Center for Clinical and Basic Research A S, Ballerup, Denmark
    Bone 34:728-35. 2004
    ..In conclusion, limited HRT administered in the early postmenopausal years offers long-lasting benefits for the prevention of postmenopausal bone loss and osteoporotic fracture...
  66. doi request reprint Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis
    Jörg Goldhahn
    Schulthess Clinic Zurich and Clinical Priority Program Fracture Fixation in Osteoporotic, Bone of AO Foundation, Davos, Switzerland
    Bone 43:343-7. 2008
    ..The study design should be randomized, parallel, double-blind, and placebo-controlled, and all fracture subjects should receive a standardized method of fracture fixation, defined as Standard of Care...
  67. ncbi request reprint The cost-effectiveness of alendronate in the management of osteoporosis
    John A Kanis
    Bone 42:4-15. 2008
    ..We conclude that alendronate is a cost-effective agent for the prevention and treatment of fractures associated with osteoporosis. These findings, suitable for informing practice guidance, contrast with recent appraisals from NICE...
  68. ncbi request reprint Critical issues in translational and clinical research for the study of new technologies to enhance bone repair
    Jörg Goldhahn
    Department of Research, Schulthess Klinik, Lengghalde 2, Zurich 8008, Switzerland
    J Bone Joint Surg Am 90:43-7. 2008
    ..The guidelines should be harmonized between European and American regulatory authorities to ensure comparability of results of studies and to foster global harmonization of regulatory requirements...
  69. ncbi request reprint Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007
    T John Martin
    Osteoporos Int 18:1019-21. 2007